Close
Patheon

Patheon Newsroom

  • 30 Mar 2017
    Company “dominated” latest industry report with approximately 30 percent of all outsourced approvals, four times more than the nearest competitor

    Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical sector, has been cited once again as capturing the most outsourced new drug approvals (NDAs) in the US than any other contract manufacturing...

  • 16 Mar 2017
    Highlights: 1Q 2017 revenue increased by 13% year-over-year to $457M Net income from continuing operations was $28M Net income from continuing operations per diluted share was $0.19 1Q 2017 Adjusted EBITDA was $83M, or 18% of revenue, a 350 bp year-over-year improvement Adjusted net income from continuing operations was $21M Adjusted net income from continuing operations per diluted share was $0.14 Updated financial outlook for fiscal year 2017

    Patheon N.V. (NYSE: PTHN), a leading global provider of pharmaceutical development and manufacturing services, today reported financial results for the quarter ended January 31, 2017.

    First quarter 2017 revenue was $457 million, an increase of 13% compared to the...

  • 03 Mar 2017

    Patheon N.V. (NYSE: PTHN), a leading global provider of pharmaceutical development and manufacturing services, today announced that it will release financial results for the first fiscal quarter 2017 on Thursday, March 16, 2017 before the market opens.

Media Contact

Mari Mansfield
4815 Emperor Blvd.,
Durham, NC 27703
(919) 226-3137
mari.mansfield@patheon.com

Patheon on Twitter

 
 

Media Contact

Mari Mansfield
4815 Emperor Blvd.,
Durham, NC 27703
(919) 226-3137
mari.mansfield@patheon.com

Patheon on Twitter